{"id":"NCT02509078","sponsor":"Massachusetts General Hospital","briefTitle":"Reevaluation Of Systemic Early Neuromuscular Blockade","officialTitle":"Reevaluation Of Systemic Early Neuromuscular Blockade","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-01-04","primaryCompletion":"2018-07-03","completion":"2019-04-04","firstPosted":"2015-07-27","resultsPosted":"2019-08-13","lastUpdate":"2019-08-13"},"enrollment":1008,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Acute Respiratory Distress Syndrome"],"interventions":[{"type":"DRUG","name":"Cisatracurium Besylate","otherNames":["Nimbex"]}],"arms":[{"label":"Early Neuromuscular Blockade (NMB)","type":"ACTIVE_COMPARATOR"},{"label":"Control: No Routine Early NMB","type":"NO_INTERVENTION"}],"summary":"This study evaluates whether giving a neuromuscular blocker (skeletal muscle relaxant) to a patient with acute respiratory distress syndrome will improve survival. Half of the patients will receive a neuromuscular blocker for two days and in the other half the use of neuromuscular blockers will be discouraged.","primaryOutcome":{"measure":"Hospital Mortality to Day 90","timeFrame":"90 days after randomization","effectByArm":[{"arm":"Early Neuromuscular Blockade (NMB)","deltaMin":288,"sd":null},{"arm":"Control: No Routine Early NMB","deltaMin":289,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.93"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":44,"countries":["United States"]},"refs":{"pmids":["31112383","27788018","27779896"],"seeAlso":["http://petalnet.org"]},"adverseEventsSummary":{"seriousAny":{"events":28,"n":501},"commonTop":["Hypotension","Pneumothorax","Pneumomediastinum","Cardiac Arrest","Hypotension"]}}